<IMG SRC"http://enewsletters.biospace.com/images/news/biospace-news-815x425-pfizer.jpg" NAME"Why Pfizer Will Not Make Another Mega M&A Deal Anytime Soon" ALT"Why Pfizer Will Not Make Another Mega M&A Deal Anytime Soon"March 15, 2017By Mark Terry, BioSpace.com Breaking…
Life Sciences Jobs ... Source: BioSpace
The FDA has issued warning letters to two API manufacturers, citing branding and data integrity issues. Source: Drug Industry Daily
Mylan reached a settlement with Roche and Genentech that paves the way for the generic drugmaker to market a biosimilar version of the blockbuster drug Herceptin. Source: Drug Industry Daily
The USPTO's Patent Trial and Appeal Board validated four of Acorda’s patents on the multiple sclerosis drug Ampyra, but a federal court still has to determine whether five of the…
Amgen is calling on the U.S. Supreme Court to rule that biosimilar makers must wait six months after an FDA approval to market their therapy. Source: Drug Industry Daily
Two FDA advisory committees voted Tuesday that the benefits of a previously approved formulation of Opana ER no longer outweigh the risks of abuse. Source: Drug Industry Daily
India’s Ministry of Health is proposing that drug regulators and drugmakers implement several measures to improve the quality of drugs in the country’s supply chain, following a government estimate that…
China’s State Council is ordering the China Food and Drug Administration to implement stricter policies for drug GMP compliance. Source: Drug GMP Report